Soberanis Pina Pamela, Lheureux Stephanie
Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Biologics. 2024 Mar 21;18:79-93. doi: 10.2147/BTT.S369783. eCollection 2024.
Endometrial cancer (EC) has a high epidemiological impact with incidence and mortality rising worldwide. In recent years, the integration of the pathologic and molecular classification has provided relevant information to understand the heterogeneity in the biology of EC, which led to the evolution in the management of patients. Currently, therapeutic breakthroughs have been made in advanced EC to improve oncologic outcomes, with efforts to include patient reported outcomes. Precision and personalized medicine are under way in EC exploring different combination approaches to target cross-talk pathways, cancer cell microenvironment, and metabolic vulnerabilities and improve drug delivery. Yet, collaborative efforts are needed to face the challenges in practice by refining patient selection, ideal biomarker identification, and de-escalation of therapies according to emerging molecular and genomic features of EC.
子宫内膜癌（EC）具有很高的流行病学影响，全球范围内其发病率和死亡率都在上升。近年来，病理和分子分类的整合为理解EC生物学的异质性提供了相关信息，这促使了患者管理方式的演变。目前，晚期EC已取得治疗突破以改善肿瘤治疗结果，并努力纳入患者报告的结果。EC领域正在推进精准和个性化医疗，探索不同的联合方法来靶向相互作用途径、癌细胞微环境和代谢弱点，并改善药物递送。然而，需要共同努力来应对实践中的挑战，通过优化患者选择、确定理想的生物标志物以及根据EC新出现的分子和基因组特征减少治疗强度。
